Poisons Act (Amendment of Schedule) Notification 2000

Status:

Published in Subsidiary Legislation Supplement
on 23 Feb 2000

Search within Legislation

Search Results

No. S 67

Poisons Act

Poisons Act (Amendment of Schedule) Notification 2000

In exercise of the powers conferred by section 3(2) of the Poisons Act, the Minister for Health hereby makes the following Notification:

Citation and commencement

1. This Notification may be cited as the Poisons Act (Amendment of Schedule) Notification 2000 and shall come into operation on 1st March 2000.

Amendment of Schedule

2. The Schedule to the Poisons Act is amended —

(a)

by inserting, immediately above the item “Abciximab”, the following item:

“Abacavir; its salts; its esters; their salts”;

(b)

by inserting, immediately below the item “Abciximab”, the following item:

“Acamprosate; its salts”;

(c)

by inserting, immediately below the item “Adreno-corticotrophic hormone (ACTH)”, the following item:

“Alatrofloxacin; its salts; its esters; their salts”;

(d)

by inserting, immediately below the item “Azapropazone”, the following item:

“Azasetron; its salts”;

(e)

by inserting, immediately below the item “Boric acid; sodium borate”, the following item:

“Botulinum Toxin, when contained in preparations intended for treatment of human ailments”;

(f)

by inserting, immediately below the item “Brimonidine; its salts”, the following item:

“Brinzolamide”;

(g)

by inserting, immediately below the item “Buprenorphine; its salts”, the following item:

“Bupropion; its salts”;

(h)

by inserting, immediately below the item “Cefuroxime”, the following item:

“Celecoxib”;

(i)

by inserting, immediately below the item “Edrophonium; its salts”, the following item:

“Efavirenz”;

(j)

by inserting, immediately below the item “Embutramide”, the following item:

“Emedastine; its salts; its esters; their salts”;

(k)

by inserting, immediately below the item “Enoxaparin; its salts”, the following item:

“Entacapone”;

(l)

by inserting, immediately below the item “Epoprostenol; its salts”, the following items:

“Eprosartan; its salts; its esters; their salts

Eptifibatide”;

(m)

by inserting, immediately below the item “Flucytosine; its salts; its esters; their salts”, the following item:

“Fludarabine phosphate”;

(n)

by inserting, immediately below the item “Fosfestrol; its salts”, the following item:

“Fosfomycin; its salts; its esters and ethers; their salts”;

(o)

by inserting, immediately below the item “Ibacitabine”, the following item:

“Ibandronic acid; its salts”;

(p)

by inserting, immediately below the item “Lenograstim”, the following item:

“Lepirudin”;

(q)

by inserting, immediately below the item “Lovastatin”, the following item:

“Loxoprofen; its salts”;

(r)

by inserting, immediately below the item “Mafenide; its salts”, the following item:

“Mangafodipir; its salts”;

(s)

by inserting, immediately below the item “Milrinone; its salts”, the following item:

“Miltefosine”;

(t)

by inserting, immediately below the item “Moclobemide”, the following item:

“Moexipril; its salts”;

(u)

by inserting, immediately below the item “Niridazole”, the following item:

“Nisoldipine”;

(v)

by inserting, immediately below the item “Orciprenaline; its salts”, the following item:

“Orlistat”;

(w)

by inserting, immediately below the item “Oxethazaine; its salts”, the following item:

“Oxidronic acid; its salts”;

(x)

by inserting, immediately below the item “Oxytocins; natural and synthetic”, the following item:

“Paclitaxel; which are intended for the treatment of human ailments”;

(y)

by inserting, immediately below the item “Promazine; its salts”, the following item:

“Promestriene”;

(z)

by inserting, immediately below the item “Quinine; its quarternary compounds, their salts”, the following item:

“Rabeprazole; its salts”;

(za)

by inserting, immediately below the item “Rafoxanide”, the following item:

“Raloxifene; its salts”;

(zb)

by inserting, immediately below the item “Rivastigmine; its salts; its esters; their salts”, the following item:

“Rizatriptan; its salts; its esters; their salts”;

(zc)

by inserting, immediately below the item “Rocuronium; its salts”, the following item:

“Rofecoxib”;

(zd)

by inserting, immediately below the item “Rolitetracycline; its salts; its esters; their salts”, the following item:

“Ropinirole; its salts”;

(ze)

by inserting, immediately below the item “Ropivacaine; its salts”, the following item:

“Rosiglitazone; its salts”;

(zf)

by inserting, immediately below the item “Teicoplanin”, the following item:

“Telmisartan”;

(zg)

by inserting, immediately below the item “Thyroxine; its salts”, the following item:

“Tianeptine; its salts”;

(zh)

by inserting, immediately below the item “Topotecan; its salts”, the following item:

“Toremifene; its salts; its esters; their salts”;

(zi)

by inserting, immediately below the item “Tranylcypromine; its salts”, the following items:

“Trastuzumab

Trazodone; its salts”;

(zj)

by inserting, immediately below the item “3, 4, 5-Trimethoxyamphetamine”, the following item:

“Trimetrexate; its salts; its esters; their salts”;

(zk)

by inserting, immediately below the item “Tropisetron; its salts”, the following item:

“Trovafloxacin; its salts; its esters; their salts”; and

(zl)

by inserting, immediately below the item “Zalcitabine”, the following item:

“Zanamivir”.

Made this 16th day of February 2000.

MOSES LEE

Permanent Secretary,
Ministry of Health,
Singapore.

[NPA(DAD) 78:01 Vol 5; AG/LEG/SL/234/97/1 Vol. 2]